Looking at 2025, Health: Breakthroughs of hope and promise
Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using a Compounding Pharmacy
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
kpvi11h
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...
24/7 Wall St13h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic
CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
McKnight's Long-Term Care News19h
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
Hold Rating on Inspire Medical Systems Amid FDA Approval of Tirzepatide for OSA
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...